粪菌移植在艰难梭菌感染合并肝硬化患者中安全有效
这项多中心回顾性研究纳入63例因艰难梭菌感染接受粪菌移植的肝硬化成人患者,粪菌移植成功率为85.7%。FMT失败组中移植时使用非CDI抗生素、Child-Pugh B或C级、使用益生菌、存在假膜及住院接受FMT的比例更高;多变量分析显示移植时使用非CDI抗生素和使用益生菌与FMT失败风险增加相关。FMT相关不良事件发生率为33.3%,多为自限性腹部绞痛或腹泻,仅5例严重不良事件可能与FMT相关,无感染或死亡。
要点
- 63例肝硬化合并CDI患者接受FMT,成功率为85.7%。
- 移植时使用非CDI抗生素和使用益生菌与FMT失败风险增加相关。
- FMT相关不良事件发生率为33.3%,多为自限性腹部绞痛或腹泻,无感染或死亡。
核心结论
- 回顾性研究显示,FMT用于肝硬化患者CDI治疗安全有效。
研究设计与样本
- 多中心回顾性研究,纳入2012年1月至2018年11月在美国、加拿大和意大利8个学术中心接受FMT治疗CDI的63例肝硬化成人患者,中位MELD评分为14.5,其中24例为失代偿期肝硬化。
主要发现
- FMT成功54例(85.7%)。
- FMT失败组与成功组比较:移植时使用非CDI抗生素44.4% vs 5.6%(P < .001),Child-Pugh B或C级100% vs 37.7%(P < .001),使用益生菌77.8% vs 24.1%(P = .003),存在假膜22.2% vs 0(P = .018),住院接受FMT 45.5% vs 19%(P = .039)。
- 多变量分析中,移植时使用非CDI抗生素(比值比17.43;95%CI 2.00-152.03;P = .01)和使用益生菌(比值比11.9;95%CI 1.81-78.3;P = .01)与FMT失败风险增加相关。
- FMT相关不良事件发生于33.3%(21/63)的患者,多为自限性腹部绞痛或腹泻;仅5例严重不良事件可能与FMT相关,无感染或死亡。
关键数值与推荐
- FMT指征:复发性CDI 55/63(87.3%),严重CDI 6/63(9.5%),暴发性CDI 2/63(3.2%)。
- FMT主要经结肠镜进行(59/63;93.7%),多数为门诊患者(47/63;76.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clostridioides difficile infection (CDI) harms a large proportion of patients with cirrhosis. Fecal microbiota transplantation (FMT) is recommended for recurrent CDI, but its effects in patients with cirrhosis have not been established. We performed a multicenter observational study to evaluate the efficacy and safety of FMT for CDI in patients with cirrhosis. METHODS: We performed a retrospective study of 63 adults with cirrhosis (median model for end-stage liver disease score, 14.5; 24 patients with decompensated cirrhosis) who underwent FMT for CDI from January 2012 through November 2018 at 8 academic centers in the United States, Canada, and Italy. We collected data on patient demographics and characteristics of cirrhosis, CDI, and FMT from medical records and compared differences among patients with different severities of cirrhosis, and FMT successes vs failures at the 8-week follow-up evaluation. We also obtained data on adverse events (AEs) and severe AEs within 12 weeks of FMT. RESULTS: Patients underwent FMT for recurrent CDI (55 of 63; 87.3%), severe CDI (6 of 63; 9.5%), or fulminant CDI (2 of 63; 3.2%) primarily via colonoscopy (59 of 63; 93.7%) as outpatients (47 of 63; 76.8%). FMT success was achieved for 54 patients (85.7%). Among FMT failures, a higher proportion used non-CDI antibiotics at the time of FMT (44.4% vs 5.6%; P < .001), had Child-Pugh scores of B or C (100% vs 37.7%; P < .001), used probiotics (77.8% vs 24.1%; P = .003), had pseudomembranes (22.2% vs 0; P = .018), and underwent FMT as inpatients (45.5% vs 19%; P = .039), compared with FMT successes. In multivariable analysis, use of non-CDI antibiotics at the time of FMT (odds ratio, 17.43; 95% CI, 2.00-152.03; P = .01) and use of probiotics (odds ratio, 11.9; 95% CI, 1.81-78.3; P = .01) were associated with a greater risk of FMT failure. FMT-related AEs occurred in 33.3% of patients (21 of 63)-most were self-limited abdominal cramps or diarrhea. There were only 5 severe AEs that possibly were related to FMT; none involved infection or death. CONCLUSIONS: In a retrospective study, we found FMT to be safe and effective for the treatment of CDI in patients with cirrhosis.
引用
- Cheng YW, Alhaffar D, Saha S, et al. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2020. PMID: 32645451. doi:10.1016/j.cgh.2020.06.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。